Newsletter
Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more

JAMA Editor’s Summary

Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more

Editor's Summary by Kristin Walter, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the issue.
February 22, 2022

Sublingual Dexmedetomidine for Agitation in Bipolar Disorder, SARS-CoV-2 Infection and Maternal Morbidity and Mortality, Neurological Outcome in Refractory Out-of-Hospital Cardiac Arrest, and more

Editor’s Summary by Kristin Walter, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the February 22, 2022 issue.

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Reading, Writing and Anxiety When pediatric mental health collides with the US healthcare system.